Gilead Sciences (GILD) Financials
Gilead Sciences (GILD) Historical Financial Statements and Key Metrics for 1996 - 2021
Full Gilead Sciences financials for 1996 - 2021 are available in the
US Historical Financials dataset
All financial data is sourced direct from SEC 10-Q and 10-K filings, restatements are included.
Gilead Sciences Income Statements
(in $ 000,000's)
| Quarter End | Revenue | Gross Profit | Operating Income | Net Income | EBITDA | EPS |
| 2021-Mar-31 | 6,423 | 5,062 (78.8 %) | 2,952 (46.0 %) | 1,729 (26.9 %) | 3,425 | 1.37 |
| 2020-Dec-31 | 7,421 | 6,023 (81.2 %) | 2,715 (36.6 %) | 1,551 (20.9 %) | 3,142 | 1.24 |
| 2020-Sep-30 | 6,577 | 5,436 (82.7 %) | 3,172 (48.2 %) | 360 (5.5 %) | 3,527 | 0.29 |
| 2020-Jun-30 | 5,143 | 4,079 (79.3 %) | -2,983 (-58.0 %) | -3,339 (-64.9 %) | -2,634 | -2.66 |
| 2020-Mar-31 | 5,548 | 4,579 (82.5 %) | 2,402 (43.3 %) | 1,551 (28.0 %) | 2,751 | 1.22 |
| 2019-Dec-31 | 5,879 | 4,196 (71.4 %) | 1,093 (18.6 %) | 2,696 (45.9 %) | 1,443 | 2.12 |
| 2019-Sep-30 | 5,604 | 4,569 (81.5 %) | -1,473 (-26.3 %) | -1,165 (-20.8 %) | -1,126 | -0.92 |
Full historical income statements for 1996 - 2021 is included in the
US Historical Financials dataset.
Gilead Sciences Balance Sheets
(in $ 000,000's)
| Quarter End | Total Assets | Total Liabilities | Total Debt | Total Equity | Cash & Equivalents |
| 2021-Mar-31 | 67,492 | 48,528 | 30,166 | 18,952 | 5,666 |
| 2020-Dec-31 | 68,407 | 50,186 | 31,402 | 18,202 | 7,408 |
| 2020-Sep-30 | 60,878 | 43,407 | 29,290 | 17,445 | 23,975 |
| 2020-Jun-30 | 55,934 | 37,792 | 24,102 | 18,027 | 18,914 |
| 2020-Mar-31 | 59,741 | 37,562 | 24,097 | 22,067 | 20,785 |
| 2019-Dec-31 | 61,627 | 38,977 | 24,593 | 22,525 | 24,352 |
| 2019-Sep-30 | 59,146 | 38,410 | 24,588 | 20,604 | 22,856 |
Full historical balance sheet data for 1996 - 2021 is included in the
US Historical Financials dataset.
Gilead Sciences Cash Flow Statements
(in $ 000,000's)
| Quarter End | Operating Cash Flow | Investing | Financing | Free Cash Flow |
| 2021-Mar-31 | 2,610 | -2,042 | -2,477 | 2,445 |
| 2020-Dec-31 | 1,916 | -8,977 | 131 | 1,735 |
| 2020-Sep-30 | 2,250 | -271 | 4,124 | 2,095 |
| 2020-Jun-30 | 2,566 | -5,023 | -874 | 2,423 |
| 2020-Mar-31 | 1,436 | -344 | -2,611 | 1,265 |
| 2019-Dec-31 | 2,580 | 431 | -896 | 2,377 |
| 2019-Sep-30 | 2,899 | -2,095 | -2,515 | 2,699 |
Full historical cash flow data for 1996 - 2021 is included in the
US Historical Financials dataset.
Gilead Sciences Key Valuation and Operating Metrics
| Quarter End | Market Capitalization ($ 000,000's) |
Enterprise Value ($ 000,000's) |
Price/Earnings ($ 000,000's) |
Price/Sales ($ 000,000's) |
Price/Book ($ 000,000's) |
| 2021-Mar-31 | 81,175 | 107,276 | 12.64 | 11.74 | 4.28 |
| 2020-Dec-31 | 73,116 | 98,521 | 9.85 | 11.79 | 4.02 |
| 2020-Sep-30 | 79,303 | 95,707 | 12.06 | 55.07 | 4.55 |
| 2020-Jun-30 | 96,560 | 113,916 | 18.77 | -7.23 | 5.36 |
| 2020-Mar-31 | 94,347 | 108,393 | 17.01 | 15.21 | 4.28 |
| 2019-Dec-31 | 82,265 | 95,227 | 13.99 | 7.63 | 3.65 |
| 2019-Sep-30 | 80,302 | 95,416 | 14.33 | -17.23 | 3.90 |
Full historical valuation and operating metrics for 1996 - 2021 are included in the
US Historical Financials dataset.